BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

Xiaohong Zhao, Yuan Ren, Matthew Lawlor, Bijal D. Shah, Paul M.C. Park, Tint Lwin, Xuefeng Wang, Kenian Liu, Michelle Wang, Jing Gao, Tao Li, Mousheng Xu, Ariosto S. Silva, Kaplan Lee, Tinghu Zhang, John M. Koomen, Huijuan Jiang, Praneeth R. Sudalagunta, Mark B. Meads, Fengdong ChengChengfeng Bi, Kai Fu, Huitao Fan, William S. Dalton, Lynn C. Moscinski, Kenneth H. Shain, Eduardo M. Sotomayor, Gang Greg Wang, Nathanael S. Gray, John L. Cleveland, Jun Qi, Jianguo Tao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Zhao et al. show that resistance to the BCL-2 inhibitor ABT-199 is conferred by super enhancer reprogramming and loss of BCL2 amplicons in models of mantle cell lymphoma and double hit lymphoma. Combining ABT-199 with the CDK7 inhibitor THZ1 prevents or reverses BCL-2 inhibitor resistance.

Original languageEnglish (US)
Pages (from-to)752-766.e9
JournalCancer Cell
Volume35
Issue number5
DOIs
StatePublished - May 13 2019

Fingerprint

B-Cell Lymphoma
Mantle-Cell Lymphoma
Lymphoma
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
2-(4'-diethylaminophenyl)benzothiazole

Keywords

  • ABT-199
  • BCL2
  • CDK7
  • THZ1
  • double-hit lymphoma
  • drug persister
  • drug resistance
  • mantle cell lymphoma
  • super-enhancer remodeling
  • transcriptome reprogramming

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Zhao, X., Ren, Y., Lawlor, M., Shah, B. D., Park, P. M. C., Lwin, T., ... Tao, J. (2019). BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell, 35(5), 752-766.e9. https://doi.org/10.1016/j.ccell.2019.04.005

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. / Zhao, Xiaohong; Ren, Yuan; Lawlor, Matthew; Shah, Bijal D.; Park, Paul M.C.; Lwin, Tint; Wang, Xuefeng; Liu, Kenian; Wang, Michelle; Gao, Jing; Li, Tao; Xu, Mousheng; Silva, Ariosto S.; Lee, Kaplan; Zhang, Tinghu; Koomen, John M.; Jiang, Huijuan; Sudalagunta, Praneeth R.; Meads, Mark B.; Cheng, Fengdong; Bi, Chengfeng; Fu, Kai; Fan, Huitao; Dalton, William S.; Moscinski, Lynn C.; Shain, Kenneth H.; Sotomayor, Eduardo M.; Wang, Gang Greg; Gray, Nathanael S.; Cleveland, John L.; Qi, Jun; Tao, Jianguo.

In: Cancer Cell, Vol. 35, No. 5, 13.05.2019, p. 752-766.e9.

Research output: Contribution to journalArticle

Zhao, X, Ren, Y, Lawlor, M, Shah, BD, Park, PMC, Lwin, T, Wang, X, Liu, K, Wang, M, Gao, J, Li, T, Xu, M, Silva, AS, Lee, K, Zhang, T, Koomen, JM, Jiang, H, Sudalagunta, PR, Meads, MB, Cheng, F, Bi, C, Fu, K, Fan, H, Dalton, WS, Moscinski, LC, Shain, KH, Sotomayor, EM, Wang, GG, Gray, NS, Cleveland, JL, Qi, J & Tao, J 2019, 'BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models', Cancer Cell, vol. 35, no. 5, pp. 752-766.e9. https://doi.org/10.1016/j.ccell.2019.04.005
Zhao, Xiaohong ; Ren, Yuan ; Lawlor, Matthew ; Shah, Bijal D. ; Park, Paul M.C. ; Lwin, Tint ; Wang, Xuefeng ; Liu, Kenian ; Wang, Michelle ; Gao, Jing ; Li, Tao ; Xu, Mousheng ; Silva, Ariosto S. ; Lee, Kaplan ; Zhang, Tinghu ; Koomen, John M. ; Jiang, Huijuan ; Sudalagunta, Praneeth R. ; Meads, Mark B. ; Cheng, Fengdong ; Bi, Chengfeng ; Fu, Kai ; Fan, Huitao ; Dalton, William S. ; Moscinski, Lynn C. ; Shain, Kenneth H. ; Sotomayor, Eduardo M. ; Wang, Gang Greg ; Gray, Nathanael S. ; Cleveland, John L. ; Qi, Jun ; Tao, Jianguo. / BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. In: Cancer Cell. 2019 ; Vol. 35, No. 5. pp. 752-766.e9.
@article{bb8d4d4d3beb49fab2fbf2ec967f7e06,
title = "BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models",
abstract = "Zhao et al. show that resistance to the BCL-2 inhibitor ABT-199 is conferred by super enhancer reprogramming and loss of BCL2 amplicons in models of mantle cell lymphoma and double hit lymphoma. Combining ABT-199 with the CDK7 inhibitor THZ1 prevents or reverses BCL-2 inhibitor resistance.",
keywords = "ABT-199, BCL2, CDK7, THZ1, double-hit lymphoma, drug persister, drug resistance, mantle cell lymphoma, super-enhancer remodeling, transcriptome reprogramming",
author = "Xiaohong Zhao and Yuan Ren and Matthew Lawlor and Shah, {Bijal D.} and Park, {Paul M.C.} and Tint Lwin and Xuefeng Wang and Kenian Liu and Michelle Wang and Jing Gao and Tao Li and Mousheng Xu and Silva, {Ariosto S.} and Kaplan Lee and Tinghu Zhang and Koomen, {John M.} and Huijuan Jiang and Sudalagunta, {Praneeth R.} and Meads, {Mark B.} and Fengdong Cheng and Chengfeng Bi and Kai Fu and Huitao Fan and Dalton, {William S.} and Moscinski, {Lynn C.} and Shain, {Kenneth H.} and Sotomayor, {Eduardo M.} and Wang, {Gang Greg} and Gray, {Nathanael S.} and Cleveland, {John L.} and Jun Qi and Jianguo Tao",
year = "2019",
month = "5",
day = "13",
doi = "10.1016/j.ccell.2019.04.005",
language = "English (US)",
volume = "35",
pages = "752--766.e9",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

AU - Zhao, Xiaohong

AU - Ren, Yuan

AU - Lawlor, Matthew

AU - Shah, Bijal D.

AU - Park, Paul M.C.

AU - Lwin, Tint

AU - Wang, Xuefeng

AU - Liu, Kenian

AU - Wang, Michelle

AU - Gao, Jing

AU - Li, Tao

AU - Xu, Mousheng

AU - Silva, Ariosto S.

AU - Lee, Kaplan

AU - Zhang, Tinghu

AU - Koomen, John M.

AU - Jiang, Huijuan

AU - Sudalagunta, Praneeth R.

AU - Meads, Mark B.

AU - Cheng, Fengdong

AU - Bi, Chengfeng

AU - Fu, Kai

AU - Fan, Huitao

AU - Dalton, William S.

AU - Moscinski, Lynn C.

AU - Shain, Kenneth H.

AU - Sotomayor, Eduardo M.

AU - Wang, Gang Greg

AU - Gray, Nathanael S.

AU - Cleveland, John L.

AU - Qi, Jun

AU - Tao, Jianguo

PY - 2019/5/13

Y1 - 2019/5/13

N2 - Zhao et al. show that resistance to the BCL-2 inhibitor ABT-199 is conferred by super enhancer reprogramming and loss of BCL2 amplicons in models of mantle cell lymphoma and double hit lymphoma. Combining ABT-199 with the CDK7 inhibitor THZ1 prevents or reverses BCL-2 inhibitor resistance.

AB - Zhao et al. show that resistance to the BCL-2 inhibitor ABT-199 is conferred by super enhancer reprogramming and loss of BCL2 amplicons in models of mantle cell lymphoma and double hit lymphoma. Combining ABT-199 with the CDK7 inhibitor THZ1 prevents or reverses BCL-2 inhibitor resistance.

KW - ABT-199

KW - BCL2

KW - CDK7

KW - THZ1

KW - double-hit lymphoma

KW - drug persister

KW - drug resistance

KW - mantle cell lymphoma

KW - super-enhancer remodeling

KW - transcriptome reprogramming

UR - http://www.scopus.com/inward/record.url?scp=85064746496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064746496&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2019.04.005

DO - 10.1016/j.ccell.2019.04.005

M3 - Article

C2 - 31085176

AN - SCOPUS:85064746496

VL - 35

SP - 752-766.e9

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 5

ER -